SLXN — Silexion Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $8.69m
- $11.47m
Annual cashflow statement for Silexion Therapeutics, fiscal year end - December 31st, millions except per share.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | |
| Standards: | — | USG | USG |
| Status: | fx Preliminary | Final | Final |
| Net Income/Starting Line | — | -5.11 | -16.5 |
| Depreciation | |||
| Non-Cash Items | — | 0.447 | 9.68 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | — | 0.087 | -1.58 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Cash from Operating Activities | — | -4.53 | -8.4 |
| Capital Expenditures | — | -0.012 | -0.022 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | — | 0.585 | 0 |
| Sale of Fixed Assets | |||
| Sale/Maturity of Investment | |||
| Cash from Investing Activities | — | 0.573 | -0.022 |
| Financing Cash Flow Items | — | — | 2.3 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | — | 0.522 | 5.1 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | — | -3.66 | -3.38 |